Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.68M P/E - EPS this Y -190.90% Ern Qtrly Grth -
Income -59.71M Forward P/E -0.05 EPS next Y 21.30% 50D Avg Chg -47.00%
Sales - PEG 0.00 EPS past 5Y - 200D Avg Chg -95.00%
Dividend N/A Price/Book N/A EPS next 5Y 12.70% 52W High Chg -99.00%
Recommedations 2.70 Quick Ratio 0.77 Shares Outstanding 39.33M 52W Low Chg 5.00%
Insider Own 4.87% ROA -79.64% Shares Float 36.94M Beta 0.34
Inst Own 22.81% ROE -239.32% Shares Shorted/Prior 2.79M/306.94K Price 0.06
Gross Margin - Profit Margin - Avg. Volume 7,783,129 Target Price 3.67
Oper. Margin - Earnings Date Mar 22 Volume 13,881,465 Change -10.36%
About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

ContraFect Corporation News
12/20/22 ContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Study
12/19/22 ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
12/13/22 ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
08:34 AM CFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection…
11/28/22 ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
11/22/22 CFRX: Exebacase to be Evaluated as Treatment for Prosthetic Joint Infections…
11/14/22 ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09/12/22 ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections
09/12/22 ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
09/01/22 CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis…
08/15/22 ContraFect Cuts Workforce After Trial Setback
08/15/22 ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08/15/22 ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
07/14/22 CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility…
07/13/22 ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
06/27/22 We're Not Very Worried About ContraFect's (NASDAQ:CFRX) Cash Burn Rate
06/14/22 Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
06/06/22 ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
05/26/22 CFRX: Results from Interim Futility Analysis in July 2022…
05/23/22 Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
CFRX Chatroom

User Image rahman122 Posted - 42 minutes from now

$CFRX If your math is good .you may know already what shorts wants . They dump 1.7 million share until now 🧘‍♂️🧘‍♂️🧘‍♂️💥💥💥 I want 3x

User Image qut Posted - 40 minutes from now

$CFRX I wrote them and told them they need to put news out. alot of people dont know. no reply yet.

User Image rahman122 Posted - 29 minutes from now

$CFRX if this 8k become a reality and they stay over nasdaq . We may 2x3x or 🚀 But I want 3x 🧘‍♂️🧘‍♂️🧘‍♂️

User Image ChampOrChump Posted - 27 minutes from now

$CFRX the company raised $7m about 45 days ago from institutional investor at much higher prices and warrants at double current prices. Do you really think they would let them get delisted?

User Image Wojakmyboi01 Posted - 27 minutes from now

$CFRX 🫵🫵👇

User Image Wojakmyboi01 Posted - 26 minutes from now

$CFRX 🫵👇👇

User Image fabietto73 Posted - 26 minutes from now

$CFRX Red to Green? Let’s Go💪🏼

User Image thenew_york Posted - 24 minutes from now

$CFRX back in for the bounce. Looking for .18-.20 minimum before the appeal decision is released.

User Image rahman122 Posted - 20 minutes from now

$CFRX I told you 🧘‍♂️🧘‍♂️🧘‍♂️💥💥💥

User Image Wojakmyboi01 Posted - 20 minutes from now

$CFRX .29

User Image chinchinbull Posted - 16 minutes from now

$CFRX 🤡 I need cheap share ,can you dump it more

User Image rahman122 Posted - 10 minutes from now

$CFRX shorts and fragile people .you are done 😀🧘‍♂️🧘‍♂️🧘‍♂️

User Image MatthewCorran2 Posted - 5 minutes from now

$CFRX $TYDE Congrats to all members who followed our plays & made profit. Don’t miss our next big alerts.` 🚀 LINK IN BIO 🚀

User Image Ikenward Posted - 1 minute from now

$CFRX This was the response I got from contacting them. 🤷‍♂️

User Image rahman122 Posted - 14 minutes ago

$CFRX I want 3x from this hare

User Image rahman122 Posted - 16 minutes ago

$CFRX if this is true shorts are 🤡. Patience will pay off🧘‍♂️🧘‍♂️🧘‍♂️💥💥💥

User Image litzke83 Posted - 20 minutes ago

$CFRX https://stocksregister.com/2023/01/30/would-i-ever-invest-in-contrafect-corporation-nasdaq-cfrx-at-any-point-in-time/

User Image rahman122 Posted - 27 minutes ago

$CFRX if you don’t how read ask 🍆

User Image chinchinbull Posted - 28 minutes ago

$CFRX cry baby is hear

User Image JustinSS55 Posted - 29 minutes ago

$CFRX off to the OTC

User Image chinchinbull Posted - 29 minutes ago

$CFRX that’s all you got 🤡 but anyway thank you . Reversal is coming

User Image UltraBearIsBorn Posted - 41 minutes ago

$CFRX Guys, I am new entry here for a possible bottom play, any price target? I am new here ...

User Image qut Posted - 45 minutes ago

$CFRX everybody waiting on news. if its a stay . good for us bad for shorts.

User Image chinchinbull Posted - 45 minutes ago

$CFRX come on 🐷 drop some cheap share for me

User Image chinchinbull Posted - 52 minutes ago

$CFRX hello shorts want to add , can you dump some cheap share for me

User Image chinchinbull Posted - 52 minutes ago

$CFRX hello , It’s clear double from this point if stay listed in nasdaq . Going to gamble some . Let’s see and hold

User Image AlGo88 Posted - 54 minutes ago


User Image TheRealWojak Posted - 56 minutes ago


User Image nicemove Posted - 1 hour ago

$CFRX I donot know what is going on here. My model tells me it will go down to 4cents... Reverse split?or delist?

User Image Next_Big_Wave Posted - 1 hour ago

$CFRX I’m not saying it’s much but slightly positive sentiment

Analyst Ratings
Maxim Group Hold Jul 14, 22
SVB Leerink Market Perform Jul 14, 22
Cantor Fitzgerald Neutral Jul 14, 22
WBB Securities Strong Buy Jun 8, 22
SVB Leerink Outperform Feb 16, 22
WBB Securities Buy Feb 2, 22
SVB Leerink Outperform Sep 9, 21
WBB Securities Speculative Buy Mar 31, 21
Cantor Fitzgerald Overweight Nov 25, 20